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 Introduction 
 Erysipelas is a frequent, acute bacterial infection of the 
dermis and hypodermis  [1, 2] . It represents a painful, er-
ythematous, expanding plaque, occasionally with hem-
orrhages, bullae and necrosis  [3, 4] . Extracutaneous 
symptoms are frequent and comprise regional lymph-
adenopathy, malaise, fever and chills  [5] . Diagnosis is 
 primarily based on the clinical picture and substantiated 
by elevated C-reactive protein and leukocytosis. Direct 
detection of the etiological agent and serology are not 
helpful in clinical routine  [3, 6, 7] . Treatment with   -lac-
tam antibiotics is sufficient in most cases  [8] . The devel-
opment and course of erysipelas is associated with sys-
temic and/or local risk factors. Systemic risk factors may 
be liver and kidney disease, heart failure, neoplasms, im-
munosuppression, diabetes, hyperuricemia, hyperlipid-
emia, hypertension, obesity, seated position, use of non-
steroidal anti-inflammatory drugs, smoking, and alcohol 
abuse  [5, 9–14] . The most important local pathogenic fac-
tor is a disruption of the epidermal barrier that serves as 
portal of entry for bacteria, thus determining the local-
ization of erysipelas. The predilection site of erysipelas in 
80–90% of all cases is the lower leg  [1, 2] . Furthermore, 
erysipelas occurs on the face in 2.5–19%, the arm in 
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2–9%, or the genital region in 0.5–2%  [1, 3, 15] . Other 
parts of the body like the thigh and the buttocks are af-
fected only exceptionally. Therefore, clinical features and 
risk factors of erysipelas in these regions are ill defined 
 [1] . The aim of the present study was to analyze the prev-
alence of erysipelas of the thigh and buttocks as well as 
their clinical characteristics and the role of systemic and 
local predisposing factors in a large cohort of patients. 
 Methods 
 The files of 1,423 consecutive erysipelas patients treated in 3 
dermatology centers in Austria (State Hospital Wiener Neustadt, 
n = 241; Medical University of Graz, n = 1,001) and Switzerland 
(University Hospital Zurich, n = 181) between January 2005 and 
December 2008 were reviewed. All 3 centers were the major der-
matological hospitals within a catchment area of approximately 
1,000,000 people each. None of the centers was a referral center 
for erysipelas, thus being representative of the population they 
service. Patients described in our study were seen during the clin-
ical routine, and erysipelas was diagnosed by a dermatologist 
based on established clinical and laboratory criteria  [3, 8, 9] . All 
relevant demographic, clinical and therapy-related parameters 
and laboratory signs of inflammation of patients with erysipelas 
on the thighs or buttocks were entered in a database. Particular 
interest was given to the identification of entry sites for bacteria, 
and local and systemic risk factors. Forty patients with erysipelas 
of the lower leg served as a control group. All controls were re-
cruited from the same period of time and matched for the par-
ticular centers. Statistical comparison between erysipelas on the 
thigh or the buttocks and the control group was performed using 
Graph Pad Prism TM (version 5.00 for Windows, Graph Pad Soft-
ware, San Diego, Calif., USA). After descriptive statistics, nomi-
nal and ordinal variables were analyzed by Fisher’s exact test. 
Scale variables were tested for Gaussian distribution by the 
D’Agostino and Pearson omnibus normality test. None of the 
scale parameters showed a Gaussian distribution. Therefore sta-
tistical analyses were performed by the Kruskal-Wallis test with 
Dunnett’s post hoc test; p values less than 0.05 were considered 
significant. All tests were two tailed.
 Results 
 Clinical Characteristics of Patients 
 The topographic distribution of erysipelas in the 
1,423 study patients was as follows: lower legs 73%, face 
13%, arms 6.7%, trunk 2.7%, and genitalia 1.9%. Erysip-
elas exclusively localized on the thigh with no involve-
ment of other parts of the leg was identified in 30 pa-
tients (2.1%) and in the gluteal region in 9 patients (0.6%) 
( table  1 ). Gluteal erysipelas often had conspicuous ir-
regular borders and a violaceous hue ( fig. 1 ). Bilateral 
manifestation was observed twice ( fig. 2 ). Erysipelas of 
the thigh had the characteristic appearance of erysipelas 
of the lower leg, but vesicles and hemorrhages were very 
rare. That indicates that local complications were rarely 
seen in this small series of patients. Pain and inguinal 
lymphadenopathy were observed significantly less often 
in erysipelas of the thigh and gluteal region. All patients 
had elevated serum levels of C-reactive protein, whereas 
initial leukocyte counts were elevated in less than half 
of the patients. In particular, the majority of patients 
with gluteal erysipelas did not have leukocytosis. Initial 
antibiotic therapy was intravenously applied in an in-
patient setting in standard dosages in all patients. In 
 Fig. 1. Hemorrhagic erysipelas of the left gluteal region in a 
61-year-old female patient. Note the violaceous hue and conspicu-
ous irregular borders. 
 Fig. 2. Bilateral gluteal erysipelas in a 70-year-old female patient 
2 years after hip arthroplasty. 
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most patients a monotherapy was sufficient; 4 patients 
with erysipelas of the thigh and 2 patients with gluteal 
erysipelas received a combination therapy of a   -lactam 
antibiotic and clindamycin. The skin of all patients was 
completely or almost completely cleared by the end of 
the intravenous therapy, but patients with gluteal ery-
sipelas had to be treated significantly longer (median of 
3 weeks) to reach regression. Depending on the response 
to intravenous therapy, the same antibiotics were con-
secutively administered after hospital discharge to the 
same proportion of patients from the 3 groups, although 
for a significantly shorter duration in patients with ery-
sipelas of the lower leg.
 Entry Sites for Bacteria 
 In the majority of patients we identified preexisting 
skin conditions with a disruption of the skin barrier, thus 
serving as entry sites for bacteria into the dermis and hy-
podermis ( table 1 ). They comprised inflammatory (rup-
tured epidermis cyst, eczema, psoriasis) or infectious 
Table 1. C linical characteristics, laboratory values and therapy of patients with erysipelas of the thigh and the gluteal region
Parameter Thigh 
(n = 30)
Gluteal region
(n = 9)
Control group 
(lower leg, n = 40)
Median age, years 47 (20–84)a 56 (35–80) 59 (24–87)
Gender (female:male) 14:16 5:4 19:21
Median disease duration before therapy, days 2 (1–5)b 3.5 (1–14) 4 (1–24)
Bacterial entry site, patients 16 (53) 8 (89) 29 (72.5)
Skin inflammation/infection 4 6 4
Wound 7 1 10
Arthropod bite 5 1 0
Toe web intertrigo 0 0 15
Body side (left/right/both sides) 14/16/0 3/4/2 22/18/0
Pain, patients 6 (20) 2 (22) 26 (65)c
Local complications, patients 1 (3)d 3 (34) 11 (27.5)
Vesicles 1 2 8
Hemorrhages 0 1 3
Necrosis 0 0 2
Inguinal lymphadenopathy, patients 11 (37) 2 (22) 30 (76)e
Extracutaneous signs/symptoms, patients
Fever and/or chills 30 (100) 9 (100) 40 (100)
Cephalea 1 (3) 1 (11) 0 (0)
Vertigo 0 (0) 1 (11) 0 (0)
C-reactive protein elevation
Total number of patients 30 (100) 9 (100) 40 (100)
Median serum levels (normal upper limit 5 mg/l), mg/l 82 (10–320) 93.5 (42–240) 51 (10–370)
Leukocyte count
Patients with leukocytosis 12 (40) 1 (11) 17 (42.5)
Median cell count (normal upper limit 11.3 ! 103), !103 cells 10 (5–22) 8 (5–12.5) 8 (3.3–20.6)
Antibiotic therapy, patients
Benzylpenicillin 12 (41) 3 (34) 17 (42.5)
Amoxicillin plus clavulanic acid 10 (33) 2 (22) 13 (32.5)
Clindamycin 4 (13) 2 (22) 8 (20)
-Lactam plus clindamycin 4 (13) 2 (22) 2 (5)
Median duration of therapy, days 13 (4–26) 21.5 (10–24)f 11.5 (7–45)
Consecutive oral antibiotic therapy, patients 20 (67) 5 (56) 20 (50)
Median duration of consecutive therapy, days 7 (5–14) 9 (7–14) 5 (1–13)g
M edians are indicated with ranges in parentheses, patient numbers with percentages.
a p = 0.03 versus control group; b p < 0.0001 versus gluteal region and control group; c p = 0.03 versus thigh and gluteal region;
d p = 0.03 versus gluteal region and control group; e p = 0.03 versus thigh and gluteal region; f p = 0.04 versus control group; g p = 0.007 
versus thigh and gluteal region.
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(impetigo contagiosa, folliculitis/perifolliculitis, mycosis, 
herpes zoster) skin diseases, wounds, or arthropod bites.
 Local Predisposing Factors 
 We identified 2 potential local risk factors, namely re-
currence of erysipelas and surgical interventions prior to 
the onset of erysipelas. Since we do not have information 
on the patients beyond the current episode of erysipelas, 
it is not clear, how many of them suffered recurrences
of erysipelas after antibiotic therapy. However, 1 patient 
with hypertension, hepatopathy and chronic lymphede-
ma due to previous inguinal lymphadenectomy had had 
5 earlier episodes of erysipelas of the thigh. Additionally, 
3 patients with erysipelas of the thigh and 2 patients with 
gluteal erysipelas had a history of prior erysipelas be-
tween 1 and 3 years before the current episode ( table 2 ). 
Thus, the recurrence rate does not seem to differ from the 
control group. The other local risk factors for erysipelas 
were previous surgical interventions within the affected 
region, which significantly outnumbered surgical proce-
dures in the control group. Nine patients with erysipelas 
of the thigh had had inguinal lymphadenectomy because 
of malignant melanoma, 1 month to 5 years before the 
onset of erysipelas (median, 13.5 months). Other surgical 
interventions comprised hysterectomy (1), excision of 
melanoma without lymphadenectomy (1) and vein strip-
ping (2). Four patients with gluteal erysipelas had under-
gone hip arthroplasty 3 months, 2 years, 8 years and 30 
years earlier.
 Systemic Predisposing Factors 
 A wide spectrum of general medical conditions sup-
posed to be systemic predisposing risk factors for erysip-
elas  [5, 9–14] was basically present in a similar percentage 
of patients in all groups ( table 2 ). In patients with gluteal 
erysipelas, the metabolic syndrome was more prevalent 
than in those patients with erysipelas of the thigh, but not 
significantly different from the control group. For erysip-
elas of the thigh, comorbidities were more diverse with 
hypertension in the first place.
 Discussion 
 In the present study erysipelas was located in the glu-
teal region in only 9/1,423 patients (0.6%) and on the 
thigh in 30 patients (2.1%). Because our study was hospi-
tal based, it is possible that the recruitment of patients 
could have been biased towards cases with severer erysip-
elas and more comorbidities. However, the health care 
systems in Austria and Switzerland typically allow for a 
direct access of patients to hospital centers without previ-
Table 2. R isk factors for the development of erysipelas of the thigh and the gluteal region
Thigh 
(n = 30)
Gluteal region
(n = 9)
Control group 
(lower leg, n = 40)
Local risk factors
Previous episodes of erysipelas, patients 4 (13) 2 (22) 8 (20)
Previous surgical intervention, patients 13 (43) 4 (44) 1 (2.5)a
Systemic risk factors
Total number of patients with systemic risk factors 19 (63) 7 (78) 32 (80)
Obesity 2 (7)b 4 (44) 15 (37.5)
Diabetes 2 (7)c 3 (34) 12 (30)
Hyperlipidemia 4 (13) 2 (22) 8 (20)
Arterial hypertension 6 (20) 2 (22) 13 (32.5)
Renal disease 2 (7) 1 (11) 7 (17.5)
Lung disease 1 (3) 1 (11) 2 (5)
Heart disease 5 (17) 0 (0) 10 (25)
Hepatic disease 3 (10) 0 (0) 1 (2.5)
Alcoholism 0 (0) 1 (11) 1 (2.5)
Smoking 4 (13) 2 (22) 5 (12.5)
P atient numbers are given with percentages in parentheses.
a p < 0.001 versus thigh and gluteal region; b p = 0.007 versus gluteal region and control group; c p = 0.017 versus gluteal region and 
control group.
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ously contacting the practice of a family physician or der-
matologist, which generally ensures a mixed collective of 
patients in the centers. The small number of patients with 
erysipelas at uncommon sites we described is in line with 
three former retrospective studies, which collectively 
found 19 cases (1.2%) of gluteal manifestation in 1,639 
patients with the diagnosis erysipelas  [12, 16, 17] . In ac-
cordance, gluteal erysipelas has been observed as compli-
cation of hip replacement in only 14 of 2,200 patients 
(0.6%) after this orthopedic intervention  [18] . The fre-
quency of postsurgical gluteal erysipelas was higher (5/25; 
20%) in one case series but major plastic interventions 
(functional gluteoplasty) for restoration of fecal conti-
nence was performed in those patients  [19] . In an addi-
tional 7 patients presented in case reports  [20–25] gluteal 
erysipelas was either associated with regional surgery or 
immunocompromise (e.g. IgG deficiency). Manifestation 
on the thigh has been described in only 12 of 244 patients 
(4.9%) in a retrospective African study  [12] and in 2 cases 
by Durupt et al.  [22] . It is not clear why erysipelas of the 
gluteal region and the thigh are so uncommon, because 
bacterial entry sites in these regions seem to be as com-
mon as for erysipelas of the lower leg. In this case, toe web 
intertrigo is the most frequent portal of entry for bacteria, 
which has been found in 37.5% of our control patients and 
in up to 66% by other authors  [9, 26] . In acute and relaps-
ing gluteal erysipelas, intertrigo of the gluteal fold has 
been described as important in that respect  [17, 22] . In the 
present study, a wide variety of potential entry sites was 
identified, which, taken together, do not have a lower 
prevalence than toe web intertrigo  [9, 27, 28] . Also, hip 
arthroplasty, a major potential predisposing factor, is 
performed very often, for example in more than 150,000 
individuals per year in Germany  [29] . Factors contribut-
ing to the low prevalence could include less pronounced 
stasis than in the lower legs, the different route of lym-
phatic vessels, a specific local microbiological milieu and 
peculiarities of the antimicrobial defense  [30, 31] . Be-
cause of the rarity of erysipelas of the buttocks and thighs, 
physicians may not be alert to this diagnosis. Because ery-
sipelas requires a specific therapy, it is important to dis-
tinguish it from differential diagnoses like panniculitis, 
thrombophlebitis, contact dermatitis or early herpes zos-
ter  [22] .
 The clinical characteristics of erysipelas of the thigh 
and gluteal region have not been outlined in detail so far. 
The morphological differences between gluteal erysipelas 
and erysipelas of the lower legs, as found in our study 
( table 1 ), may result from distinct routes of lymphatic ves-
sels, less stasis compared to the lower leg, and/or mechan-
ical pressure due to sitting. The relatively low number of 
lymphadenopathy in erysipelas of the gluteal region or 
the thigh compared to erysipelas of the lower legs  [32] is 
in accordance with the literature on erysipelas at atypical 
sites  [17, 22, 25] . A possible explanation may be the dis-
ruption of lymphatic vessels by earlier hip arthroplasty or 
elimination of lymph nodes by inguinal lymphadenec-
tomy.
 A main goal of our study was to identify local and sys-
temic predisposing factors for erysipelas of the gluteal re-
gion and the thigh. In previous studies on about 2,000 
patients with erysipelas of the lower leg, as well as in our 
control patients (data not shown), chronic venous insuf-
ficiency and lymphedema with 25% each were the most 
important predisposing conditions  [5, 9, 13, 27, 33, 34] . In 
the gluteal region, surgical impairment of the lymphatic 
circulation has been proposed to be a predisposing factor 
for erysipelas  [16, 17, 22] . Lymph stasis after disruption of 
lymphatic vessels causes retention of high-molecular-
weight proteins within the interstitial tissue leading to 
fibrosis with reduced tissue drainage capacity resulting 
in a vicious cycle  [33, 34] . This may also disturb the mi-
gration of dendritic cells  [35] , which could weaken the 
immunological response to pathogenic agents. Indeed, a 
postsurgical impairment of lymph circulation must be 
assumed in almost half of our patients of both groups, 
mostly due to hip arthroplasty or inguinal lymphadenec-
tomy. Gluteal erysipelas has been described to develop at 
any time from 1 month  [21] to decades  [22] after surgical 
intervention, which is quite similar to our patients’ series 
(3 months to 30 years). The time frame for erysipelas of 
the thigh after surgery was more uniform, with a median 
of 13.5 months. A wide range of systemic medical condi-
tions has been linked to erysipelas of the lower leg, in-
cluding insufficiency of internal organs, metabolic and 
malignant diseases, drug ingestion and smoking  [5, 
9–14] . For example, obesity represents an unambiguous 
risk factor  [9, 27] , whereas the role of diabetes is less clear 
 [5, 9, 10, 27] . Only 1 study on gluteal erysipelas described 
concurrent systemic disorders, including hypertension, 
ischemic heart disease, and obesity but their pathogenet-
ic impact has not been elucidated  [16] . In our patients 
with gluteal erysipelas, among a wide variety of comor-
bidities, obesity and less so diabetes, hyperlipidemia, and 
smoking were the only factors that were more common 
than in the general population  [36, 37] . Remarkably, the 
prevalence of heart disease was highest in the leg group, 
which could have contributed to pronounced stasis in this 
localization. In erysipelas of the thigh, arterial hyperten-
sion was the only frequent internal disease, but hyperten-
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sion and other conditions were clearly underrepresented 
compared to erysipelas of the lower leg and the general 
population. This may be a contributing factor for the low 
frequency of erysipelas in that area. The clinical response 
to antibiotic therapy was generally good as in earlier stud-
ies  [12, 16, 18, 22, 25] , but slower in patients with gluteal 
erysipelas. This is reflected by a (significantly) longer du-
ration of intravenous therapy, the longest administra-
tion of the consecutive oral antibiotic, and the frequent 
combination of antimicrobials (  -lactam antibiotic plus 
clindamycin). The recurrence rate, obtained from the pa-
tients’ history in this study, is compatible with the pro-
portion of about one third of patients reported in the lit-
erature  [18, 21, 22, 24] . Thus, the recurrence rate of ery-
sipelas of the thigh or gluteal region is similar to that of 
the lower leg in our control group and in former studies 
 [38, 39] . All 6 patients with recurrences in our study had 
multiple local and systemic risk factors, such as regional 
surgery, which has also been observed by other authors 
 [22] .
 In summary, erysipelas of the thigh and even more so 
of the gluteal region are very rare skin affections. They 
particularly occur at any time after surgical interven-
tions, especially hip arthroplasty or inguinal lymphade-
nectomy. Not a single systemic comorbidity represents a 
statistically significant risk factor for erysipelas in atypi-
cal sites, although the metabolic syndrome appears to be 
more common in patients with gluteal erysipelas.
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